



Saving Limbs, Saving Lives

Adlore

Redefining the standard of care by bringing clinical-grade wound healing into every home.

Invest Now

\$0.84

\$250.32


Share Price

Min Investment

SEC Filings

Investor Agreement

This Reg CF offering is made available through Pivotal Crowdfunding, LLC (SEC's Registered Crowdfunding). This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.



Opportunity

Following years of rigorous clinical scholarship and university-led research, Adlore is transitioning from R&D to market commercialization. Our flagship system, SenLore, leverages a patented dual-action approach—combining electrical stimulation and thermal therapy—to treat DFUs where they are most vulnerable: at home.

With clinical data showing a dramatic increase in healing efficiency over current standards, Adlore is uniquely positioned to scale a solution that saves limbs and restores lives for the 37 million Americans living with diabetes. This platform for people with diabetes and a diabetic foot ulcer will be developed for other wounds and pathologies that have decreased blood flow. Dr. Lawson's current and past scholarship: [//daryl.lawson.academia.edu](http://daryl.lawson.academia.edu).

Our Vision

Adlore: Restoring Mobility and Dignity

Adlore envisions a future where a diabetic diagnosis never leads to a lost limb. We are disrupting the \$15B DFU crisis by bringing clinical-grade recovery directly from the hospital to the home. This mission is critical for everyone in the world, especially for those in rural communities and people of color, who currently face disproportionately higher amputation rates due to healthcare gaps.

Through our patented SenLore system—featuring unique non-adhesive insole electrodes combined with safe heat and a 3x perfusion-boosting "whirlpool" stimulation pattern—we achieve up to a 70% healing rate, nearly triple the industry standard. By bridging "health deserts" and saving up to \$17,000 per patient annually, we don't just treat ulcers; we restore independence. At Adlore, we don't just heal wounds—we save lives.

Treatment Insole—ES Activation Pattern




Image 1 of 2

Market Opportunity

Disrupting the \$15B DFU Crisis

Adlore disrupts the \$15B Diabetic Foot Ulcer (DFU) crisis with a healing rate of up to 70%—nearly triple the industry standard. Our innovation lies in non-adhesive insole electrodes and a unique "whirlpool" electrical stimulation

Market Opportunity

Disrupting the \$15B DFU Crisis

Adlore disrupts the \$15B Diabetic Foot Ulcer (DFU) crisis with a healing rate of up to 70%—nearly triple the industry standard. Our innovation lies in non-adhesive insole electrodes and a unique "whirlpool" electrical stimulation pattern that increases blood flow by 3x compared to traditional two-electrode systems.

By preventing complications, we save \$17,000 per patient annually and avoid amputations, which cost up to \$100,000. Our Remote Patient Monitoring (RPM) platform bridges rural "health deserts," slashing recurrence rates by 40%. Adlore transforms chronic wound care into a scalable, high-ROI ecosystem, delivering massive investor value and life-changing patient outcomes.

DFU Prevalence and Costs

Diabetic Foot Ulcers (DFUs) are a worldwide problem


- Every 2 seconds someone develops a DFU
- They account 8% of amputations
- Cost \$100,000+ there is no cure
- Annual U.S. treatment cost per patient \$10,000-\$15,000

U.S. DFU Prevalence

1.5M people
10% of U.S.
100,000 people
10% each year

100,000 people
10% each year

U.S. Diabetic Foot Ulcer Treatment cost is estimated to be \$1.5B-\$2B per year



Reasons to Invest

Proven Results

SenLore achieves up to 70% healing rates versus 25% with standard care.

Growing Market

DFU treatment costs exceed \$11 billion annually in the U.S. alone.

Defensible Moat

A comprehensive, multi-jurisdictional patents (Canada, EU, and the US) portfolio protects SenLore's therapy, sensors, and therapeutic boots, securing our competitive advantage."



About Us

Discover who we are, how we operate, and where we're headed. In this section, you can explore the business model, traction to date, financial highlights, and meet the team behind the vision.

BUSINESS OVERVIEW

After decades as a clinician treating the devastating reality of diabetic foot ulcers and as a researcher proving we can triple healing rates, I realized academic papers alone wouldn't save limbs—innovation would. My journey from the classroom at 3 Universities to the helm of Adlore is driven by a singular mission: to move life-saving technology out of the lab and into the homes of those who need it most. As a professor and scientist, I've vetted the data; as a CEO, I am scaling the solution. Join us in ending the amputation crisis.





of those who need it most. As a professor and scientist, I've vetted the data; as a CEO, I am scaling the solution. Join us in ending the amputation crisis.

TRACTION & MILESTONES

Adlore is currently in the pre-commercialization phase, scaling our clinically validated technology with up to a70% healing rate toward market entry. We are on target to complete a functional prototype of the SenLore monitoring and treatment system by December 2026.

Our 2027 roadmap is aggressive:

- Clinical Trials & 510(k): Launching trials and submitting for FDA clearance in January, leveraging established predicates to accelerate the regulatory timeline.
- IP Defense: Prioritizing the maintenance and expansion of our robust, multi-jurisdictional patent portfolio.

By bridging the gap between university research and commercial deployment, Adlore is positioning itself as the primary disruptor in the \$11B limb-preservation market

BUSINESS MODEL

Adlore is disrupting the multi-billion-dollar wound care market with SenLore, a high-margin hardware solution manufactured for under \$500. Our model leverages established RPM CPT codes (99453, 99454, 99457) to align clinician incentives with superior patient outcomes through recurring reimbursements.

By combining proprietary consumables with data-driven hardware, we create a scalable, high-ROI ecosystem. We are targeting high-volume entry points like the VA, Kaiser, and the NHS via E-Codes/HCPCS. With two clear exit paths—a strategic acquisition (with early interest already secured) or full-scale commercialization.

ADLORE INTELLECTUAL PROPERTY PORTFOLIO

- United States – Granted:
- US 11,013,910 — P-100A (Granted)
 - US 12,011,584 — P-100B (Granted)
 - US 11,338,128 — P-101A (Granted)
 - US 12,403,299 — P-101B (Granted)



Our Team



Entire clinician and academic career devoted to DFU/wound research. Expertise with electro-physiology an... [Read more](#)

Daryl Lawson, PT, MPT, DSc
CEO



Assistant Professor, Virginia Tech, Department of Biomedical Engineering and Director Experimental Learn... [Read more](#)

Chris Arena, PhD
Engineering Advisor




Managing Director and Founder of CFOx. Experience working with over 40 investor-backed start ups. Extens...
[Read more](#)

Matt Alessi
 CFO

Financial Snapshot

Explore key figures that highlight our financial position and growth potential.



Disclaimer: Financial snapshot figures are based on the 2025 reviewed financials.

Investment Details

Explore key details of our raise, including terms, valuation, and planned use of funds.

<p>Term ></p> <p>Overview of offering structure and key investment details.</p>	<p>Terms</p> <p>Security Type Equity</p> <p>Security Price \$0.84</p> <p>Min Investment \$250.32</p> <p>Raise Target \$9,999.36 - \$1,000,000.68</p>	<p>Up to \$1,000,000.68 in Common Stock at \$0.84 per share with a minimum target amount of \$9,999.36.</p> <p>Offering Minimum: \$9,999.36 11,904 shares of Common Stock Offering Maximum: \$1,000,000.68 1,190,477 shares of Common Stock</p> <p>Type of Security Offered: Common Stock Purchase Price of Security Offered: \$0.84 per Share Minimum Investment Amount (per investor): \$250.32 298 shares of Common Stock</p> <p><i>The Minimum Individual Purchase Amount accepted under this Regulation CF Offering is \$250.32. The Company must reach its Target Offering Amount of \$9,999.36 by June 30, 2026 (the "Offering Deadline"). Unless the Company raises at least the Target Offering Amount of \$9,999.36 under the Regulation CF offering by the Offering Deadline, no securities will be sold in this Offering, investment commitments will be cancelled, and committed funds will be returned.</i></p>
<p>Valuation ></p> <p>Company value guiding investment terms and security type.</p>		
<p>Use of Proceeds ></p> <p>How the company plans to use raised funds.</p>		
<p>SEC Filings ></p> <p>Access full regulatory filings for complete offering details.</p>		

Ask the Founders

Join the discussion! Ask Adlore, Inc.'s team any questions you have about the company or their raise.



Ask the Founders

Join the discussion! Ask Adlore, Inc.'s team any questions you have about the company or their raise.

BK What's on your mind? Ask a question...

Sign Out

No questions yet. Be the first to ask the founders!

Investor FAQs

Investment Process

- How do I create an account and start investing? ▾
- What information do I need to provide? ▾
- What payment methods are accepted? ▾
- When is my investment actually finalized? ▾
- Can I cancel my investment after I make it? ▾

Understanding the Raise

- Where can I find details about Adlore, Inc.'s financials and valuation? ▾
- What types of securities am I buying (equity, SAFE, debt, etc.)? ▾
- What happens if we don't reach our minimum funding target? ▾
- Where can I learn more about this raise? ▾

Risks & Returns

- What are the risks of investing in early-stage opportunities? ▾
- When and how could I see a return on my investment? ▾
- Is my investment liquid? Can I sell my shares? ▾

After Investing

- What happens to my money after the raise ends? ▾
- How do I track my investment over time? ▾
- Will I receive updates from Adlore, Inc. on my investment? ▾
- Are there tax implications resulting from my investment? ▾

Compliance & Security

- Is my personal and financial information secure? ▾
- What happens if I run into an issue with my investment? ▾



What happens if we don't reach our minimum funding target? ▼

Where can I learn more about this raise? ▼

Risks & Returns

What are the risks of investing in early-stage opportunities? ▼

When and how could I see a return on my investment? ▼

Is my investment liquid? Can I sell my shares? ▼

After Investing

What happens to my money after the raise ends? ▼

How do I track my investment over time? ▼

Will I receive updates from Adlore, Inc. on my investment? ▼

Are there tax implications resulting from my investment? ▼

Compliance & Security

Is my personal and financial information secure? ▼

What happens if I run into an issue with my investment? ▼



LinkedIn



Instagram



Facebook



X

Quick Links

- [Invest](#)
- [About Us](#)
- [Investor FAQs](#)
- [Company FAQs](#)
- [Resource Center](#)
- [Contact Us](#)

Products

- [Crowdfunding Marketplace](#)
- [Transfer Agent Services](#)
- [Cap Table Management](#)
- [InvestLink](#)
- [Special Purpose Vehicle](#)

Risk Disclaimer

WHEN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING. THIS INCLUDES ANALYZING THE MERITS AND RISKS INVOLVED WITH INVESTING IN THE OFFERING. INVESTMENTS ON HIGHLANDER AI ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK. THIS RISK INCLUDES THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT. INVESTMENTS ARE NOT INSURED BY THE FDIC, SIPC, OR ANY OTHER GOVERNMENT AGENCY AND MAY BE LONG-TERM OR NON-TRANSFERABLE.

Important Information

Unless otherwise stated, all securities-related activity is conducted by PicMil Crowdfunding (d/b/a Highlander Crowdfunding), a funding portal registered here with the U.S. Securities and Exchange Commission (SEC) and a member of the Financial Industry Regulatory Authority (FINRA). Highlander Crowdfunding is not a registered broker-dealer, and all escrow services are handled by Enterprise Bank and Trust and Luminate Bank, registered escrow agents.

Transfer agent services are provided by Highlander Fortress, LLC, a separate legal entity from Highlander Crowdfunding. Highlander Fortress does not participate in securities offerings and does not provide investment, legal, or tax advice.

Highlander Crowdfunding is compensated with an up-front fee and a percentage of funds raised in each offering. Fees vary between offerings, and investors should review the applicable Form C on each offering page for full fee disclosures.

Regulation Crowdfunding offerings (JOBS Act Title III) made through Highlander Crowdfunding are open to both accredited and non-accredited investors. These securities offerings are not reviewed, approved, or recommended by any federal or state securities commission or regulatory authority. Highlander Crowdfunding does not provide investment advice and does not verify the adequacy, accuracy, or completeness of information provided by the issuer. Investors should be aware that no level of due diligence beyond what is required by law is performed, and Highlander Crowdfunding does not guarantee the legitimacy or viability of any issuer or offering.

By accessing this site and any pages on this site, you agree to be bound by our Terms of Use, Privacy Policy and Investor User Agreement. Past performance is not indicative of future results.

